Xiuzheng Pharmaceutical Group Aims For A-Share Listing
This article was originally published in PharmAsia News
Xiuzheng Pharmaceutical Group plans to go for A-share listing at the end of this year or early 2009, according to the company's president. As a TCM enterprise, Xiuzheng ranks among China's top 10 pharmaceutical corporations with its revenue of 5.7 billion yuan in 2007. The company will begin constructing its biomedical industry park with 1 billion yuan. With the biomedical industry its second largest core business, it aims to create value in the capital market for investors. An analyst notes that going public is inevitable for Xiuzheng, but whether it is the right move at a time when China's stock market is slowing down remains to be seen. (Click here for more - Chinese Language)
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.